Frontiers in psychiatry
January 1, 2022
S Parker Singleton, Julie B Wang, Michael Mithoefer et al.
36 citations
In nine veterans and first-responders with chronic PTSD, MDMA-assisted therapy (MDMA-AT) did not significantly increase amygdala-hippocampus resting-state functional connectivity as hypothesized, showing only a trend. After treatment, brain activation during trauma memory recall decreased in the cuneus. Recovery from PTSD correlated with changes in four functional connections during autobiographical memory recall: left amygdala with left and right posterior cingulate cortex and left insula, and left isthmus cingulate with left posterior hippocampus. These findings suggest that amygdala, hippocampus, and insula functional connectivity may be a target of MDMA-AT, highlighting regions involved in memory processes.
Neuropharmacology
August 17, 2022
Jack E Henningfield, Marion A Coe, Roland R Griffiths et al.
34 citations
New medicines containing classic hallucinogenic and entactogenic psychedelics like psilocybin, LSD, and MDMA are being developed for psychiatric and neurological disorders. These substances are currently Schedule I under the US Controlled Substances Act (CSA) and similarly controlled globally. The CSA framework governs research, drug approval, and rescheduling; upon FDA approval, a drug containing a Schedule I substance must be rescheduled. Abuse potential research informs the eight CSA factors used for rescheduling, as well as product labeling and required risk evaluation and mitigation strategies (REMS). Standard human abuse potential studies are problematic for strong hallucinogens like psilocybin, so alternative strategies are discussed. Abuse-related research may also illuminate mechanisms of action, therapeutic effects, and effects on brain, behavior, mood, spirituality, and consciousness.
Drug and alcohol dependence
May 1, 2026
Juan Carlos C Montoy, Ralph C Wang, Allison R Coker et al.
From 2002 to 2019, first-time use of any hallucinogen among US civilians aged 12 and older averaged 0.71% per year, with a small but statistically significant increase (odds ratio 1.009 per year). New use decreased among 12- to 17-year-olds (OR 0.96) and increased among those 65 and older (OR 1.56). LSD showed a notable rise (OR 1.08 per year), while psilocybin and MDMA did not. From 2021 to 2023, 0.79% reported new hallucinogen use, with no overall change (OR 0.97). Patterns of first-time use vary by substance and age group, with adolescents using less and older adults using more.
Current topics in behavioral neurosciences
November 22, 2025
Maha N Mian, Allison R Coker, Grace Kretzer et al.
Communities that use psychedelics as religious sacraments have developed their own frameworks for safety and hold distinct views on risk and harm. To better understand their lived realities, researchers can collaborate closely with these communities using community-based participatory research (CBPR) practices, which center communities in co-creating research, improve engagement, build trust, and highlight local priorities. This paper presents preliminary findings from a CBPR study with entheogenic communities, sharing lessons learned from forming a community advisory board and initial pilot data gathering. Lessons include consulting community engagement experts, considerations for compensation and confidentiality, using multimodal recruitment strategies, and recognizing the unique historical context of these communities. These lessons aim to develop best practices for psychedelic research, policy, and public education.